PortfoliosLab logoPortfoliosLab logo
CNCR vs. NUKZ
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

CNCR vs. NUKZ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Range Nuclear Renaissance ETF (NUKZ). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CNCR vs. NUKZ - Yearly Performance Comparison


Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

NUKZ

1D
2.19%
1M
-9.62%
YTD
5.84%
6M
3.06%
1Y
75.22%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CNCR vs. NUKZ - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than NUKZ's 0.85% expense ratio.


Return for Risk

CNCR vs. NUKZ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

NUKZ
NUKZ Risk / Return Rank: 9393
Overall Rank
NUKZ Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
NUKZ Sortino Ratio Rank: 9595
Sortino Ratio Rank
NUKZ Omega Ratio Rank: 8989
Omega Ratio Rank
NUKZ Calmar Ratio Rank: 9696
Calmar Ratio Rank
NUKZ Martin Ratio Rank: 9090
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. NUKZ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Range Nuclear Renaissance ETF (NUKZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CNCR vs. NUKZ - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


CNCRNUKZDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.38

Sharpe Ratio (All Time)

Calculated using the full available price history

1.78

Dividends

CNCR vs. NUKZ - Dividend Comparison

CNCR has not paid dividends to shareholders, while NUKZ's dividend yield for the trailing twelve months is around 0.86%.


TTM20252024
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%0.00%
NUKZ
Range Nuclear Renaissance ETF
0.86%0.91%0.09%

Drawdowns

CNCR vs. NUKZ - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum NUKZ drawdown of -33.03%. Use the drawdown chart below to compare losses from any high point for CNCR and NUKZ.


Loading graphics...

Drawdown Indicators


CNCRNUKZDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-33.03%

+33.03%

Max Drawdown (1Y)

Largest decline over 1 year

-16.51%

Current Drawdown

Current decline from peak

0.00%

-9.62%

+9.62%

Average Drawdown

Average peak-to-trough decline

0.00%

-6.10%

+6.10%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.28%

Volatility

CNCR vs. NUKZ - Volatility Comparison


Loading graphics...

Volatility by Period


CNCRNUKZDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.47%

Volatility (6M)

Calculated over the trailing 6-month period

21.64%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

31.77%

-31.77%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

32.60%

-32.60%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

32.60%

-32.60%